Pyxis Oncology, Inc.
PYXS
$1.03
-$0.01-0.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -128.06% | 8.01% | -8.80% | 83.08% | 56.80% |
| Total Depreciation and Amortization | -20.29% | 39.77% | 11.64% | 487.37% | 259.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,036.92% | -60.86% | -45.57% | -27.71% | -85.42% |
| Change in Net Operating Assets | -184.40% | 294.40% | 597.84% | -78.28% | -145.51% |
| Cash from Operations | -26.46% | 16.60% | 72.74% | 22.84% | 12.27% |
| Capital Expenditure | -- | 100.00% | 100.00% | 94.62% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 160.65% | 70.37% | 100.02% | 80.78% | -- |
| Cash from Investing | 160.63% | -100.12% | 100.02% | 81.39% | 650.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 85.19% | 4,114.41% | -97.50% | -- | -- |
| Repurchase of Common Stock | 100.00% | 99.75% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 300.00% | 1,067.84% | -98.20% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 246.84% | -16.41% | 89.35% | 114.50% | 73.75% |